Serina Therapeutics Receives Recommendation From Independent Safety Monitoring Committee To Continue Its Phase 1b Registrational Trial Of SER-252 To Cohort 2
Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced
Serina's medicine test passed a safety check, so they can keep testing it on more people. When a medicine passes safety reviews, it's a good sign the company might be on the right track, though early tests don't guarantee it will work.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.